M. Sekip Altunkan/LinkedIn
Nov 19, 2026, 13:26
M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
M. Sekip Altunkan, Associate Professor and Internal Medicine Specialist at a Private Medical Practice, shared a post on LinkedIn:
“When the antidote that halts a fatal bleed triggers a secondary catastrophe.
Targeted reversal with andexanet alfa rapidly arrests factor Xa inhibitor-associated hemorrhage, yet clinicians often underestimate the prothrombotic rebound created by TFPI inhibition colliding with a vulnerable vascular bed.
A new pooled analysis of the ANNEXA-I and ANNEXA-4 cohorts uncovers a distinct temporal split between early arterial clots and late venous events—identifying the exact patient subgroups facing the steepest mortality penalty and how anticoagulation resumption shifts the balance.”
Stay updated with Hemostasis Today.
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance
-
Nov 19, 2026, 12:56Batool Abuhalimeh: The Hidden Psychological Burden of Pulmonary Embolism
-
Nov 19, 2026, 12:45Pedro Perez: PE Recovery – From Acute Treatment to Long-Term Follow-Up
-
Nov 19, 2026, 12:34Edward Lee Carter: Are We Ready for FXIa Inhibitors?
-
Nov 19, 2026, 12:19Essama Telli: When a Bruise Doesn’t Heal – Recognising the Warning Signs
-
Nov 19, 2026, 11:51Wolfgang Miesbach: Beyond Episomal Gene Therapy in Haemophilia B
-
Nov 19, 2026, 11:18A First Look at WFH CCS 2027
-
Nov 19, 2026, 10:58Does a Higher Measured Factor Level Always Mean Better Protection Against Joint Bleeds? – Global Hemophilia Report